Episode 24: A Between the Biotech Waves conversation with John Hoffman, managing director & head of healthcare equity capital markets at Credit Suisse
Between the Biotech Waves
The Depressing Future of Biotech
The best thing about the new year is that it's not 2022. So I think we're all happy to be operating in 2023. The telling up here from me today around predictions for 23 is going to be a whole lot more optimistic than what they were during 2022. There was a lot of cross currents, both on the macro side and the biotech side specifically that just created a really, really tough operating environment.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
